Electromedical Technologies Inc (EMED)

[Winsmore]

Sorry, meant to reply to TeacherMan. Below is some information I was able to find with the help of AI. It’s been a long road and somehow, I did not realize just how long a roll-up and merger before Lionheart Health’s independent IPO would actually take. It’s obvious that Lionheart Health has done an amazing job preparing for the IPO and I have confidence that it will be very successful given Howard Leonhardt’s incredible vision, background, track record and experience. I’m still holding my shares and still believe that the real value will come from shares in Lionheart’s IPO, even at a lower share conversion ratio than maybe we expected. I can’t see taking a loss and selling at .0001 when there may be a chance for a much greater return in the long run. There is also a possibility that the stock price will pop once we get a PR or the S-1 is filed publicly. It all depends on your own individual trading strategy. JMHO.

Financial and Strategic Realities

The $500,000 loan was highly likely a bridging capital arrangement structured for discounted equity. In a pre-IPO consolidation or roll-up strategy, a primary partner (Lionheart Health) often extends short-term debt to a financially strained target (EMED) to keep operations afloat until the IPO triggers. It serves to keep the target company solvent while legal and valuation frameworks are being drawn up.

Since EMED defaulted, it creates a tactical pivot point. Rather than initiating hostile liquidation, a corporate default in a friendly pre-IPO rollup typically gives the lender more leverage.

Matthew Wolfson (CEO of EMED) may very well be navigating deliberate delays to leverage a better deal, but his hand is weak.

Leverage: EMED possesses the manufacturing infrastructure, established sales channels, and historical device distribution networks that Lionheart needs to scale immediately.

Vulnerability: EMED’s May 20, 2026, Q1 report showing poor financials and their status as an alternative reporting company (having filed Form 15 to suspend SEC reporting) signals that they are running out of runway.

Wolfson is likely trying to negotiate higher valuation metrics for EMED shareholders in the final S-1 roll-up equity split, but Lionheart holds the leverage because of the debt default.

Because Lionheart is targeting an IPO, Howard Leonhardt will want a clean, reputationally safe resolution. The most probable path includes:

The "Debt-for-Equity" Friendly Rollup: To avoid public legal disputes that look bad on a pre-IPO S-1 filing, Lionheart could agree to forgive the $500,000 default in exchange for absorbing EMED completely. In this scenario, EMED shareholders would likely receive shares in the private Lionheart entity (or a specific allocation during the IPO transition). However, due to EMED's weak financial position, the conversion ratio would significantly dilute EMED’s existing equity.


Manufacturing: The Mettler Electronics, Anaheim, CA, connection.

EMED and Lionheart are actively utilizing Mettler Electronics in Anaheim, CA to anchor the new device platform.
This allows Lionheart to market a “Made in California” device backed by Mettler’s decades of reliable medical manufacturing.

The Design Alignment: Leonhardt Ventures' internal goal documents explicitly state their intent to "Launch sales USA and worldwide on Mettler 240 platform via Lionheart Health non-dilution path." The device known as the Lionheart 240 Stimulus™ is heavily built upon or derived from the Mettler Electronics Sys*Stim 240 neuromuscular stimulator architecture. Mettler is a legacy manufacturer in Anaheim, CA with existing FDA 510(k) clearances, making them an ideal OEM partner to quickly scale stable hardware. Mettler Electronics frequently acts as an OEM (Original Equipment Manufacturer) for clinical electrotherapy hardware, supplying standard casings and boards that companies then customize.


The Lionheart 240 Stimulus™ consists of:

EMED Proprietary Components / iDNA tech
Mettler Outer Shell/Core Power Architecture – Integrates the numbers of Mettler’s FDA-cleared Sys*Stim 240 hardware to leverage pre-existing regulatory clearances.
Lionheart Bioelectric Signaling Protocols

The core value proposition of the Lionheart 240 Stimulus is the integration of EMED’s WellnessPro Infinity digital synthesis/iDNA technology alongside Lionheart’s patented software protocols for bioelectric protein expression.

The strategic partnership combines Lionheart's patented bioelectric signaling software with different physical hardware units. The various device name changes from EMED’s WellnessPro Infinity 240 to the current pictured Lionheart 240 Stimulus™ gradually distanced the device from the micro-cap EMED brand, positioning it under the Lionheart IPO – a clear transition from an EMED-owned asset to a Lionheart-controlled technology.


Why Two Similar Versions Exist on the Website

https://lionhearthealthstim.com/medspas-clinics-order/

On the Lionheart Health Stim portal, both the WellnessPro Infinity, Legacy EMED portable/pod platform ($14,995) and the Lionheart Stimulus 240, Mettler Electronics Sys*Stim platform ($6,195) appear because they target entirely different market segments and regulatory pathways.

They essentially do the same basic biological task—delivering electrical current to stimulate tissue. However, keeping both options live lets the company capture two distinct price points while maintaining cash flow from EMED’s existing pre-orders during the transition.


Product Branding & Manufacturing

Mettler Electronics & the 240: The Lionheart 240 Stimulus has distinct hardware that closely resembles the Mettler Sys*Stim 240 neuromuscular stimulator. Mettler Electronics frequently acts as an OEM (Original Equipment Manufacturer) for clinical electrotherapy hardware, supplying standard casings and boards that companies then customize.

Why Two Devices? The WellnessPro Infinity and Lionheart 240 Stimulus are both shown because they target different customer bases. The Infinity is historically positioned as a general-use or at-home unit, while the 240 Stimulus is tailored strictly for clinical aesthetics and longevity protocols (e.g., hair/skin regeneration) inside Lionheart MedSpas.

Medical Offices and the VA: The WellnessPro Infinity will likely continue to be marketed to medical offices and the VA, as it carries an FDA 510(k) clearance for pain management. Lionheart Health plans to program these legacy devices with their own patented bioelectric signaling protocols to broaden the treatment modalities.

EMED's Sales Team: EMED previously onboarded a medical group with hundreds of sales reps. However, as the roll-up progresses, these sales efforts are likely being folded into Lionheart's overarching 124-location international Longevity MedSpa expansion to push proprietary "membership" programs.